Skip to main content
. 2021 Jan 5;35(5):1143–1151. doi: 10.1111/jdv.17071

Figure 3.

Figure 3

CJM112 multiple dosing (MD) reduction in PASI over time. Line graph demonstrating mean percentage change of PASI from baseline to Week 12 following multiple dosing of CJM112 compared with placebo and secukinumab. PASI, Psoriasis Area Severity Index.